In recent years, immune checkpoint inhibitor (ICI) therapy has been successful in metastatic TNBC.[17] ICI therapy is directed against the interaction between the programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1).[18] PD-1 is a co-inhibitory molecule expressed by activated T-cells when antigen-presenting cells or tumor cells are combined with PD-L1, which further lead to inhibiting the T-cell activation and suppressing the body’s antitumor immune response.[19]. This evidence concerns the gene PDCD1 and neoplasm.